Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New strategy aims to tame dangerous side effect of promising cancer drug

NCT ID NCT05663866

Ongoing Symptom relief Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing three different medications—dexamethasone, montelukast, and methotrexate—to see if they can prevent or lessen severe allergic-like reactions that can happen during the first dose of a lung cancer drug called amivantamab. It involves 68 people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to make the amivantamab infusion safer and more tolerable for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • CHU Rouen Hopital Charles Nicolle

    Rouen, 76000, France

  • CHU de Brest - Hopital de la Cavale Blanche

    Brest, 29200, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Changhua Christian Hospital

    Changhua, 500, Taiwan

  • Chi-Mei Medical Center, Liouying

    Tainan, 73657, Taiwan

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, 28644, South Korea

  • Compassionate Cancer Care

    Fountain Valley, California, 92708, United States

  • Gachon University Gil Medical Center

    Incheon, 21565, South Korea

  • Hopital Cochin

    Paris, 75014, France

  • Hopital Europeen Georges-Pompidou

    Paris, 75015, France

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • Hosp Virgen de La Victoria

    Málaga, 29010, Spain

  • Hosp. Clinico Univ. Lozano Blesa

    Zaragoza, 50009, Spain

  • Hosp. Clinico Univ. de Santiago

    Santiago de Compostela, 15706, Spain

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, 28007, Spain

  • Hosp. Gral. Univ. Valencia

    Valencia, 46014, Spain

  • Hosp. San Pedro de Alcantara

    Cáceres, 10003, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Hosp. Univ. Quiron Dexeus

    Barcelona, 8028, Spain

  • Hosp. Univ. Son Espases

    Palma de Mallorca, 07120, Spain

  • Hosp. de Jerez de La Frontera

    Jerez de la Frontera, 11407, Spain

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, 08025, Spain

  • Inst. Cat. Doncologia-H Duran I Reynals

    L'Hospitalet de Llobregat, 08908, Spain

  • Inst. Valenciano de Oncologia

    Valencia, 46009, Spain

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, 80756, Taiwan

  • National Cancer Center

    Gyeonggi-do, 10408, South Korea

  • National Taiwan University Hospital

    Taipei, 10043, Taiwan

  • Nouvel Hopital Civil - CHU Strasbourg

    Strasbourg, 67091, France

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Medical University

    Taipei, 110, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • UW Medicine Valley Medical Center

    Renton, Washington, 98055, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL CELL LUNG